18:30 , Aug 31, 2018 |  BC Week In Review  |  Company News

JW grants Leo rights to atopic dermatitis candidate JW1601

JW Pharmaceutical Corp. (KSE:001060) granted Leo Pharma A/S (Ballerup, Denmark) exclusive rights to develop and commercialize JW1601 worldwide, excluding Korea. This year, JW expects to submit an IND in Korea for a Phase I trial...
02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
17:12 , Jul 21, 2017 |  BioCentury  |  Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc., the $50.5 million round announced July 20 is...
21:57 , Dec 30, 2016 |  BC Week In Review  |  Company News

Ziarco, Novartis deal

Novartis will acquire Ziarco for undisclosed financial terms. The deal gives the pharma ZPL-389, an oral histamine H4 receptor (HRH4; H4) antagonist. Ziarco previously said ZPL-389 missed the primary endpoint but significantly reduced Eczema Area...
23:24 , Dec 16, 2016 |  BC Extra  |  Company News

Novartis gets eczema candidate in Ziarco takeout

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring Ziarco Group Ltd. (Canterbury, U.K.). The deal gives the pharma ZPL-389, an oral histamine H4 receptor (HRH4; H4) antagonist that has completed a Phase IIa trial to treat moderate...
07:00 , Jun 16, 2016 |  BC Innovations  |  Targets & Mechanisms

Vedanta's horizons

Vedanta Biosciences Inc. has followed up its March double-hit of publishing preclinical proof of concept for its homegrown, microbiome-based therapies and in-licensing a new technology to expand the portfolio, with its closing last week of...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

ZPL-389: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 98 patients with moderate to severe atopic dermatitis showed that once-daily 30 mg oral ZPL-389 missed the primary endpoint of improving NRS for pruritus from...
01:11 , May 17, 2016 |  BC Extra  |  Clinical News

Ziarco planning atopic dermatitis Phase IIb

Ziarco Group Ltd. (Canterbury, U.K.) said ZPL-389 missed the primary endpoint of pruritus as measured on a numerical rating scale vs. placebo in a 98-patient Phase IIa study to treat moderate to severe atopic dermatitis....
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

ZPL-389: Phase IIa started

Ziarco began a double-blind, placebo-controlled, international Phase IIa trial to evaluate 30 mg oral ZPL-389 once daily for 12 weeks in about 120 patients with moderate to severe psoriasis. Ziarco has exclusive, worldwide rights to...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

ZPL-398: Phase IIa started

Ziarco began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 30 mg ZPL-398 once daily for 8 weeks in 90 patients with moderate to severe atopic dermatitis. Ziarco Group Ltd., Canterbury, U.K.   Product: ...